SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice

[1]  C. Granziera,et al.  Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study , 2022, Nature Communications.

[2]  T. Woodruff,et al.  SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein , 2022, Molecular Psychiatry.

[3]  A. Iwasaki,et al.  The neurobiology of long COVID , 2022, Neuron.

[4]  V. Kasatkin,et al.  The Impact of Mild COVID-19 on Executive Functioning and Mental Health Outcomes in Young Adults , 2022, Healthcare.

[5]  Z. Al-Aly,et al.  Long-term neurologic outcomes of COVID-19 , 2022, Nature Medicine.

[6]  M. Taquet,et al.  Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients , 2022, The Lancet Psychiatry.

[7]  G. Gkoutos,et al.  Symptoms and risk factors for long COVID in non-hospitalized adults , 2022, Nature Medicine.

[8]  Lisa E. Gralinski,et al.  SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice , 2022, Science Translational Medicine.

[9]  J. Switzer,et al.  Neuropsychiatric sequelae of long COVID-19: Pilot results from the COVID-19 neurological and molecular prospective cohort study in Georgia, USA , 2022, Brain, Behavior, & Immunity - Health.

[10]  A. Tanuri,et al.  From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics , 2022, Biochemical Engineering Journal.

[11]  G. Alter,et al.  Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae , 2022, medRxiv.

[12]  S. Khan,et al.  Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant , 2022, Virology.

[13]  Peter J Hellyer,et al.  Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort , 2022, eClinicalMedicine.

[14]  Weihong Song,et al.  The synapse as a treatment avenue for Alzheimer’s Disease , 2022, Molecular Psychiatry.

[15]  B. Haagmans,et al.  SARS-CoV-2 pathogenesis , 2022, Nature Reviews Microbiology.

[16]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[17]  S. Kushner,et al.  The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2 , 2022, Trends in Neurosciences.

[18]  R. Perlis,et al.  SARS-CoV-2 promotes microglial synapse elimination in human brain organoids , 2022, bioRxiv.

[19]  M. Merad,et al.  Pathological sequelae of long-haul COVID , 2022, Nature Immunology.

[20]  M. Peluso,et al.  Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19 , 2022, Annals of clinical and translational neurology.

[21]  Jinpyo Hong,et al.  SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death , 2022, Scientific Reports.

[22]  Nelson B Rodrigues,et al.  Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis , 2021, Brain, Behavior, and Immunity.

[23]  S. Maier,et al.  SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties , 2021, Brain, Behavior, and Immunity.

[24]  Tony Y. Hu,et al.  Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates , 2020, Nature Communications.

[25]  Benjamin J. Polacco,et al.  Evolution of enhanced innate immune evasion by SARS-CoV-2 , 2021, Nature.

[26]  Suji Kim,et al.  Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells , 2021, Viruses.

[27]  Arvid Edén,et al.  Author Response: CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series , 2021, Neurology.

[28]  P. Edison,et al.  Long covid—mechanisms, risk factors, and management , 2021, BMJ.

[29]  P. Xie,et al.  BoDV‐1 infection induces neuroinflammation by activating the TLR4/MyD88/IRF5 signaling pathway, leading to learning and memory impairment in rats , 2021, Journal of medical virology.

[30]  V. Felipo,et al.  A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease , 2021, Journal of clinical medicine.

[31]  H. Bartsch,et al.  Long COVID in a prospective cohort of home-isolated patients , 2021, Nature Medicine.

[32]  I. Cobos,et al.  Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.

[33]  M. Hallek,et al.  Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 , 2021, EMBO molecular medicine.

[34]  L. Petrucelli,et al.  Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19 , 2021, Science Translational Medicine.

[35]  Kenneth A. Matreyek,et al.  Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies , 2021, Journal of extracellular vesicles.

[36]  M. Filippi,et al.  Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients , 2021, Journal of Neurology.

[37]  T. Cokelaer,et al.  COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters , 2021, Science Translational Medicine.

[38]  K. Blennow,et al.  Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness , 2021, medRxiv.

[39]  C. V. von Bartheld,et al.  Expression of the ACE2 virus entry protein in the nervus terminalis reveals the potential for an alternative route to brain infection in COVID-19 , 2021, bioRxiv.

[40]  A. Banerjee,et al.  Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study , 2021, BMJ.

[41]  C. Taylor,et al.  Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers” , 2021, Annals of clinical and translational neurology.

[42]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[43]  Xiangxi Wang,et al.  SARS-CoV-2 spike protein interacts with and activates TLR41 , 2021, Cell Research.

[44]  M. Peluso,et al.  Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients , 2021, Journal of NeuroVirology.

[45]  M. Peluso,et al.  Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations , 2021, Cells.

[46]  T. Kizaki,et al.  SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages , 2021, Heliyon.

[47]  M. Peluso,et al.  Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients , 2021, Journal of neurovirology.

[48]  D. Raoult,et al.  18F-FDG brain PET hypometabolism in patients with long COVID , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  R. Heads,et al.  COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation , 2021, Mediators of inflammation.

[50]  M. Prinz,et al.  The roles of microglia in viral encephalitis: from sensome to therapeutic targeting , 2021, Cellular & Molecular Immunology.

[51]  H. Zetterberg,et al.  SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  O. Olajide,et al.  SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia , 2020, bioRxiv.

[53]  G. Nuovo,et al.  Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein , 2020, Annals of Diagnostic Pathology.

[54]  G. Fabbrocini,et al.  From SARS-CoV-2 hematogenous spreading to endothelial dysfunction: clinical-histopathological study of cutaneous signs of COVID-19 , 2020, Diagnostic Pathology.

[55]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[56]  W. Banks,et al.  The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice , 2020, Nature Neuroscience.

[57]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[58]  A. Tenner,et al.  The good, the bad, and the opportunities of the complement system in neurodegenerative disease , 2020, Journal of Neuroinflammation.

[59]  A. Tenner,et al.  The good, the bad, and the opportunities of the complement system in neurodegenerative disease , 2020, Journal of neuroinflammation.

[60]  Ashish Ranjan Sharma,et al.  Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex , 2020, Infection, Genetics and Evolution.

[61]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[62]  C. Ko,et al.  Discordant anti‐SARS‐CoV‐2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein , 2020, Journal of cutaneous pathology.

[63]  Chu-Chung Huang,et al.  Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study , 2020, EClinicalMedicine.

[64]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[65]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2020, bioRxiv.

[66]  K. Blennow,et al.  Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 , 2020, Neurology.

[67]  Xianwei Wang,et al.  Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer’s Disease , 2020, Frontiers in Neuroscience.

[68]  A. Benachi,et al.  Transplacental transmission of SARS-CoV-2 infection , 2020, Nature Communications.

[69]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[70]  K. Fukuchi,et al.  TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease , 2020, Frontiers in Immunology.

[71]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[72]  M. Navarrete,et al.  TLR4 pathway impairs synaptic number and cerebrovascular functions through astrocyte activation following traumatic brain injury , 2020, bioRxiv.

[73]  L. Schneider,et al.  The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease , 2020, Alzheimer's Research & Therapy.

[74]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[75]  Zongze Zhang,et al.  Toll-like receptor 4 deficiency ameliorates β2-microglobulin induced age-related cognition decline due to neuroinflammation in mice , 2020, Molecular Brain.

[76]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[77]  wei zhang,et al.  The Immune System Drives Synapse Loss During Lipopolysaccharide-Induced Learning and Memory Impairment in Mice , 2019, Front. Aging Neurosci..

[78]  S. Ferreira,et al.  Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice , 2019, Nature Communications.

[79]  A. Semlali,et al.  Toll‐like receptor 4 polymorphisms in Saudi population with cardiovascular diseases , 2019, Molecular genetics & genomic medicine.

[80]  J. Poirier,et al.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation , 2019, Alzheimer's & Dementia.

[81]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[82]  Zhuangzhuang Chen,et al.  The role of microglia in viral encephalitis: a review , 2019, Journal of neuroinflammation.

[83]  E. Greenfield Sampling and Preparation of Mouse and Rat Serum. , 2017, Cold Spring Harbor protocols.

[84]  K. Tyler,et al.  Molecular mechanisms of neuroinflammation and injury during acute viral encephalitis , 2017, Journal of Neuroimmunology.

[85]  G. Tononi,et al.  Sleep Loss Promotes Astrocytic Phagocytosis and Microglial Activation in Mouse Cerebral Cortex , 2017, The Journal of Neuroscience.

[86]  John D Lambris,et al.  More than complementing Tolls: complement–Toll‐like receptor synergy and crosstalk in innate immunity and inflammation , 2016, Immunological reviews.

[87]  Robert E. Schmidt,et al.  A complement–microglial axis drives synapse loss during virus-induced memory impairment , 2016, Nature.

[88]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[89]  Veeranna,et al.  Neurofilament Subunits are Integral Components of Synapses and Modulate Neurotransmission and Behavior In Vivo , 2015, Molecular Psychiatry.

[90]  Ping Liu,et al.  Correlation of Hippocampal Volume and Cognitive Performances in Patients with Either Mild Cognitive Impairment or Alzheimer's disease , 2015, CNS neuroscience & therapeutics.

[91]  D. Finn,et al.  CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. , 2015, Cerebral cortex.

[92]  Tyrone D. Cannon,et al.  Maternal complement C1q and increased odds for psychosis in adult offspring , 2014, Schizophrenia Research.

[93]  Koanhoi Kim,et al.  Distinct Dictation of Japanese Encephalitis Virus-Induced Neuroinflammation and Lethality via Triggering TLR3 and TLR4 Signal Pathways , 2014, PLoS pathogens.

[94]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[95]  N. Sarvetnick,et al.  TLR signaling controls lethal encephalitis in WNV-infected brain , 2014, Brain Research.

[96]  N. Agrawal,et al.  Toll-like receptor 4 polymorphisms and their haplotypes modulate the risk of developing diabetic retinopathy in type 2 diabetes patients , 2014, Molecular vision.

[97]  G. Malerba,et al.  Polymorphism −2604G>A variants in TLR4 promoter are associated with different gene expression level in peripheral blood of atherosclerotic patients , 2013, Journal of Human Genetics.

[98]  Yen-Ching Chen,et al.  Sequence Variants of Toll Like Receptor 4 and Late-Onset Alzheimer's Disease , 2012, PloS one.

[99]  R. Panizzutti,et al.  Astrocyte-induced Synaptogenesis Is Mediated by Transforming Growth Factor β Signaling through Modulation of d-Serine Levels in Cerebral Cortex Neurons* , 2012, The Journal of Biological Chemistry.

[100]  Ben A. Barres,et al.  Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner , 2012, Neuron.

[101]  Jin-Tai Yu,et al.  Common variants in toll-like receptor 4 confer susceptibility to Alzheimer's disease in a Han Chinese population. , 2012, Current Alzheimer research.

[102]  L. Tan,et al.  Genetic association of TLR4/11367 polymorphism with late-onset Alzheimer's disease in a Han Chinese population , 2011, Brain Research.

[103]  D. Postma,et al.  Toll-like receptor 2 and 4 genes influence susceptibility to adverse effects of traffic-related air pollution on childhood asthma , 2010, Thorax.

[104]  Anders M. Fjell,et al.  Hippocampal volumes are important predictors for memory function in elderly women , 2009, BMC Medical Imaging.

[105]  Choung-Soo Kim,et al.  The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. , 2009, Cancer genetics and cytogenetics.

[106]  Sung-Chun Tang,et al.  Toll-like receptors in neurodegeneration , 2009, Brain Research Reviews.

[107]  S. Santi,et al.  Hippocampal hypometabolism predicts cognitive decline from normal aging , 2008, Neurobiology of Aging.

[108]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[109]  A. Garenne,et al.  Borna Disease Virus Infection Impairs Synaptic Plasticity , 2007, Journal of Virology.

[110]  E. Ling,et al.  Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.

[111]  C. Vorhees,et al.  Morris water maze: procedures for assessing spatial and related forms of learning and memory , 2006, Nature Protocols.

[112]  G. Almazan,et al.  Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice , 2006, Virology.

[113]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[114]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[115]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.